P697: Thiopurines vs. anti-TNFa for the prevention of postoperative recurrence in Crohn’s disease—a meta-analysisECCO '18 Vienna
2018
P698: Early dose optimisation in non-responders to golimumab induction treatment for ulcerative colitis is supported by pharmacokinetic dataECCO '18 Vienna
2018
P699: Radiologic response reduces the risk of small-bowel surgery in Crohn’s diseaseECCO '18 Vienna
2018
P700: A high CRP before surgery and early medical prophylaxis predict postoperative endoscopic Crohn’s disease recurrenceECCO '18 Vienna
2018
P701: Quality of life of patients with inflammatory bowel diseases who live with an ostomy: Results of a French national surveyECCO '18 Vienna
2018
P703: Clinical, radiographic and endoscopic remission with vedolizumab treatment in Crohn’s diseaseECCO '18 Vienna
2018
P704: Ustekinumab induces limited mucosal healing after 6 months in a real-life, prospective cohort of patients with refractory Crohn’s diseaseECCO '18 Vienna
2018
P705: Switching from originator to biosimilar infliximab—real-world data from 18 months prospective follow-up of a single-centre IBD populationECCO '18 Vienna
2018
P706: Lower need for adalimumab dose intensification in IBD patients treated with combined immune suppression compared with adalimumab monotherapyECCO '18 Vienna
2018
P707: Increasing abundance of faecalibacterium prausnitzii is associated with decreased intestinal inflammation in Crohn’s disease: A longitudinal studyECCO '18 Vienna
2018
P708: Home-based infusion therapy for biologic agent administration as a therapeutic option for patients with inflammatory bowel diseaseECCO '18 Vienna
2018
P709: Is there a difference in adalimumab drug levels according to pen vs. syringe use: An international, multi-centre retrospective analysisECCO '18 Vienna
2018
P710: Efficacy of therapeutic intervention for ulcerative colitis patients with the Mayo Endoscopic Score of 1ECCO '18 Vienna
2018
P711: A pilot study using point of care testing for infliximab and faecal calprotectin in IBD patients with a secondary loss of responseECCO '18 Vienna
2018
P712: Establishing pharmacokinetic equivalence between adalimumab and ABP 501 in the presence of anti-drug antibodies using population PK modellingECCO '18 Vienna
2018
P713: Home-based vedolizumab infusions: A suitable alternative to routine hospital infusionsECCO '18 Vienna
2018